Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: Meta-analysis of primary prevention trials

Heart Rhythm

Volumn 10, Issue 2, 2013, Pages 200-206

  Katritsis, Demosthenes G ^a   Siontis, Konstantinos C ^b,c   Bigger, J Thomas ^d   Kadish, Alan H ^e   Steinman, Richard ^d   Zareba, Wojciech ^f   Siontis, George C M ^b   Bardy, Gust H ^g   Ioannidis, John P A ^b,h  

^a Athens Euroclinic   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c MAYO CLINIC   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g Seattle Institute for Cardiac Research   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Implantable cardioverter defibrillator; Left ventricular ejection fraction; Meta analysis; Primary prevention; QRS duration

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QRS INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; AGED; COMPARATIVE STUDY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME;

AGED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84882252648     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.10.039     Document Type: Article

References (35)

1. Theuns, D.A., Smith, T., Hunink, M.G., Bardy, G.H., Jordaens, L., Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 12 (2010), 1564–1570.
2. Desai, A.S., Fang, J.C., Maisel, W.H., Baughman, K.L., Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 292 (2004), 2874–2879.
3. Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51 (2008), e1–e62.
4. Zipes, D.P., Camm, A.J., Borggrefe, M., et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006), e385–e484.
5. Buxton, A.E., Lee, K.L., Hafley, G.E., et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 50 (2007), 1150–1157.
6. Hohnloser, S.H., Kuck, K.H., Dorian, P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004), 2481–2488.
7. Steinbeck, G., Andresen, D., Seidl, K., et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 361 (2009), 1427–1436.
8. Fishman, G.I., Chugh, S.S., Dimarco, J.P., et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 122 (2010), 2335–2348.
9. Goldenberg, I., Vyas, A.K., Hall, W.J., et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51 (2008), 288–296.
10. Bardy, G.H., Lee, K.L., Mark, D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
11. Kadish, A., Dyer, A., Daubert, J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004), 2151–2158.
12. Moss, A.J., Zareba, W., Hall, W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002), 877–883.
13. Moss, A.J., Hall, W.J., Cannom, D.S., et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996), 1933–1940.
14. Ioannidis, J.P., Trikalinos, T.A., The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMA 176 (2007), 1091–1096.
15. Lau, J., Ioannidis, J.P., Schmid, C.H., Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997), 820–826.
16. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
17. Ioannidis, J.P., Patsopoulos, N.A., Evangelou, E., Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335 (2007), 914–916.
18. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151 (2009), W65–W94.
19. Bansch, D., Antz, M., Boczor, S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105 (2002), 1453–1458.
20. Bigger, J.T. Jr, Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337 (1997), 1569–1575.
21. Goldenberg, I., Gillespie, J., Moss, A.J., et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 122 (2010), 1265–1271.
22. Moss, A.J., Fadl, Y., Zareba, W., Cannom, D.S., Hall, W.J., Defibrillator Implantation Trial Research Group, Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 88 (2001), 516–520.
23. Wilber, D.J., Zareba, W., Hall, W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (2004), 1082–1084.
24. Kumar, S., Sivagangabalan, G., Zaman, S., et al. Electrophysiology-guided defibrillator implantation early after ST-elevation myocardial infarction. Heart Rhythm 7 (2010), 1589–1597.
25. Poole, J.E., Johnson, G.W., Hellkamp, A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359 (2008), 1009–1017.
26. Bode, F., Wiegand, U., Raasch, W., Richardt, G., Potratz, J., Differential effects of defibrillation on systemic and cardiac sympathetic activity. Heart 79 (1998), 560–567.
27. Goldenberg, I., Moss, A.J., Hall, W.J., et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation 113 (2006), 2810–2817.
28. Germano, J.J., Reynolds, M., Essebag, V., Josephson, M.E., Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. Am J Cardiol 97 (2006), 1255–1261.
29. Malasana, G., Daccarett, M., Kuppahally, S., Wasmund, S.L., Litwin, S.E., Hamdan, M.H., High prevalence of right ventricular dysfunction in ICD patients with shocks: a potential new predictor in risk stratification. J Interv Card Electrophysiol 31 (2011), 165–169.
30. Kearney, M.T., Fox, K.A., Lee, A.J., et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 40 (2002), 1801–1808.
31. Schinkel, A.F., Elhendy, A., van Domburg, R.T., et al. Prognostic significance of QRS duration in patients with suspected coronary artery disease referred for noninvasive evaluation of myocardial ischemia. Am J Cardiol 104 (2009), 1490–1493.
32. Elhendy, A., Hammill, S.C., Mahoney, D.W., Pellikka, P.A., Relation of QRS duration on the surface 12-lead electrocardiogram with mortality in patients with known or suspected coronary artery disease. Am J Cardiol 96 (2005), 1082–1088.
33. Yerra, L., Anavekar, N., Skali, H., et al. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 3 (2006), 313–316.
34. Ioannidis, J.P., Garber, A.M., Individualized cost-effectiveness analysis. PLoS Med, 8, 2011, e1001058.
35. Katritsis, D.G., Josephson, M.E., Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?. Europace 14 (2012), 787–794.